Quantcast

Latest Takeda Pharmaceutical Company Limited Stories

2014-09-09 12:29:08

Primary Research Provides Key Insights and Tools for Health Care Professionals DEERFIELD, Ill. and ALEXANDRIA, Va., Sept. 9, 2014 /PRNewswire/ -- Today, the American Diabetes Association (Association) and Takeda Pharmaceuticals, U.S.A., Inc. (Takeda) unveiled ConnecT2Day(TM), a program based on innovative research that offers new tools for health care professionals (HCPs) who are looking for additional ways to partner with patients in managing their type 2 diabetes. ConnecT2Day gathered input...

2014-09-03 16:29:02

Takeda Stresses Continued Confidence in ACTOS DEERFIELD, Ill. and OSAKA, Japan, Sept. 3, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that judgment was entered on the jury verdict that was returned on April 7, 2014, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064). The court...

2014-08-28 12:30:33

No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study OSAKA, Japan, Aug. 28, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities including the United States (U.S.) Food and Drug Administration (FDA), the European Medicines Agency...

2014-07-10 08:29:02

OSAKA, Japan and DURHAM, N.C., July 10, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during multiple poster and oral sessions at the upcoming Alzheimer's Association International Conference(®) 2014 (AAIC(®)), taking place in Copenhagen, Denmark from July 12-17, 2014. "Studies show that individuals with mild cognitive impairment--a slight, although noticeable and measurable...

2014-06-16 12:29:02

DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of a new biologic therapy, ENTYVIO((TM) )(vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). "We understand how a great need still exists for additional treatment options...

2014-06-16 08:27:34

Takeda and Lundbeck to Present Late-breaker at International College of Neuropsychopharmacology World Congress VANCOUVER, British Columbia, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated the effect of Brintellix 10-20 mg/d on aspects of cognitive function, using an objective neuropsychological test (the Digit Symbol Substitution Test or DSST) associated with executive...

2014-05-20 20:22:08

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio((TM)) (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). ( ) "Entyvio is a new option that...

2014-04-08 00:22:26

DEERFIELD, Ill., April 8, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 the jury found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Eli Lilly. The trial began...

2014-03-31 16:26:29

EMERYVILLE, Calif. and OSAKA, Japan, March 31, 2014 /PRNewswire/ -- Trianni, Inc. ("Trianni") and Takeda Pharmaceutical Company Limited ("Takeda") jointly announced today that they have entered into a license agreement for Takeda's use of the Trianni Mouse, a monoclonal antibody discovery platform. Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the...

2014-03-27 08:34:15

Sub-analyses Investigate the Effects of alogliptin on Cardiovascular Mortality Rates and Hospitalization for Heart Failure in Type 2 Diabetes Patients with Recent Acute Coronary Syndrome WASHINGTON and OSAKA, Japan, March 27, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome)...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'